Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis
Pooled result · MACEResult — go to the resultOdds ratio 0.87 95% CI 0.79–0.94Authors' conclusion
Tirzepatide is associated with a significant reduction in MACE in subjects with T2DM or overweight/obesity.
Study context
- Population
- Adults with T2DM or overweight/obesity in RCTs with follow-up ≥24 weeks
- Participants
- 29,023 adults22 trials
- Comparison
- Tirzepatide vs control
- Outcome
- MACE
Methodological detailsfixed-effects model, trial sequential analysis, Overall risk of bias was low
- Fixed-effects model
- Trial sequential analysis
- Overall risk of bias was low
Pooled result
As reported in the abstract
Odds ratio
0.87
95% CI 0.79–0.94
Tirzepatidevs Control
OR 0.87 (95% CI 0.79–0.94)
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| All-cause mortality | 0.84 (0.75–0.93) | |
| 0.512Odds ratio (log scale) |
MACE dose-response
- Lower odds of MACE per 1 mg increase in tirzepatide dose
- 2.8%
Individual MACE components and HF hospitalisations
- No association for individual components of MACE or HF hospitalisations
Original publication
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →